Status:
RECRUITING
Developping a a Brain-controlled Art App to Ease Residual Symptoms of Depression
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
Depression
Eligibility:
All Genders
25-65 years
Phase:
NA
Brief Summary
The study evaluate the effect of 10 neurofeedback sessions on the residual symptoms of depressive patients in partial remission.
Eligibility Criteria
Inclusion
- Subjects aged 25 to 65 included
- Information and signed informed consent
- Patients with a diagnosis of major depressive episode in remission
- MADRS score between 14 and 22
- Patients with residual symptoms as assessed by MADRS items
- No cognitive impairment.
- Right-handed
Exclusion
- Subjects with legal incapacity or limited legal capacity
- Subjects unlikely to cooperate with the study and/or poor cooperation anticipated by the investigator
- Pregnant women
- Subjects in the exclusion period of another study or is on the "national volunteer list".
- Subjects with another psychiatric pathology (bipolar mood disorder, psychosis, obsessive-compulsive disorder, addictive pathology, schizophrenia)
- Subjects under a protective measure such as guardianship or safeguard of justice.
Key Trial Info
Start Date :
October 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT06098469
Start Date
October 10 2024
End Date
February 1 2025
Last Update
November 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Besançon
Besançon, France, 25000